Accelr8 Announces Development Expansion for Blood-Based Diagnostic Tests
November 22 2011 - 7:30AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced that
it successfully completed two technical feasibility studies for
test methods that expand its BACcel™ rapid diagnostic test library
and automation capabilities. The first is a same-day
multi-pathogen, multiple drug resistance diagnostic panel for
positive blood cultures. Blood-borne infections produce extremely
low bacterial or fungal counts in blood, so all blood tests require
an overnight culture before testing. As with other specimen types,
standard culture tests require colony isolation and then additional
tests to identify pathogens and specific drug resistance
expression. These require 2-3 additional days after obtaining a
positive culture. Some of the new molecular diagnostic methods,
such as mass spectrometry (“MALDI-TOF”), also require isolates and
some require further sample extraction for best accuracy.
Accelr8 adapted its respiratory infection test methods to
provide same-day results for positive blood cultures. The blood
test panel includes multiple pathogens and multiple drug resistance
types for each pathogen. The BACcel™ tests can report results by
the end of the second day after obtaining a blood specimen, rather
than 3-4 days.
The second project developed an innovative method for automating
specimen preparation. Patient specimens typically contain a large
proportion of materials that interfere with organism extraction or
analysis. Reducing this content can markedly improve test accuracy
for most test methods, including the BACcel™ system. Accelr8’s new
technology reduces the total preparation time from about 45 minutes
with the existing respiratory specimen cleanup to less than 10
minutes. Development uses Accelr8’s latest BACcel™ lab prototype
fluidics robot to automate most of the operation.
The company believes that the new BAC-Xtrax™ device will
completely integrate a “specimen-to-answer” automated BACcel™
system. It can also stand alone as a lab product, or integrate into
other companies’ automated systems for processing patient
specimens.
“In addition to our own development plan, we’ve received
requests from medical opinion leaders and from other companies for
these new capabilities. We will submit presentations to major
medical congresses where these advances will have the greatest
impact,” said David Howson, the company’s president. “We continue
to expand our network of medical and commercial collaborators as we
enhance the BACcel’s performance for long-term leadership in
clinical diagnostic and pharmaceutical development markets. We are
in dialogue with potential US, European, and Chinese
collaborators,” he concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may
be “forward-looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Statements regarding
future prospects and developments are based upon current
expectations and involve certain risks and uncertainties that could
cause actual results and developments to differ materially from the
forward-looking statement, including those detailed in the
company's filings with the Securities and Exchange Commission.
Accelr8 does not undertake an obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024